

Western Pacific Regional Action Agenda on Regulatory Strengthening, Convergence and Cooperation for Medicines and the Health Workforce



Western Pacific Regional Action Agenda on Regulatory Strengthening, Convergence and Cooperation for Medicines and the Health Workforce

© World Health Organization 2019

ISBN 978 92 9061 894 2

Some rights reserved.

This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition". Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules>).

Suggested citation. Western Pacific regional action agenda on regulatory strengthening, convergence and cooperation for medicines and the health workforce. Manila, Philippines, World Health Organization Regional Office for the Western Pacific. 2019. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. 1. Delivery of health care – standards. 2. Drug monitoring – standards. 3. Health workforce. 4. Regional health planning. I. World Health Organization Regional Office for the Western Pacific. (NLM Classification: W84.1).

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>. For WHO Western Pacific Regional Publications, request for permission to reproduce should be addressed to Publications Office, World Health Organization, Regional Office for the Western Pacific, P.O. Box 2932, 1000, Manila, Philippines, Fax. No. (632) 521-1036, email: wpropuballstaff@who.int.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Photo credits:

Cover: ©WHO/A. Brookes

pp. 1, 7, 39, 67, 73: ©WHO/Y. Shimizu – pp. 4, 12, 68: ©WHO/P. Sensouphone – p. 62: ©WHO/A. Mendoza

CONTENTS

Abbreviations.....	iv
Executive summary.....	v
1. INTRODUCTION.....	1
2. SITUATIONAL ANALYSIS.....	4
3. ANALYTICAL FRAMEWORK.....	7
3.1 Regulatory functions.....	7
3.2 Regulatory governance.....	9
3.3 Regulatory approaches and implementation.....	9
3.4 Regulatory convergence mechanisms.....	10
4. REGULATION OF MEDICINES.....	12
4.1 Regional overview.....	13
4.2 Performance of regulatory functions.....	21
4.3 Key issues and challenges.....	28
4.4 Regulatory convergence and cooperation in medicines.....	29
5. REGULATION OF THE HEALTH WORKFORCE.....	39
5.1 Regional overview.....	40
5.2 Performance of regulatory functions.....	44
5.3 Key issues and challenges.....	51
5.4 Ensuring comparability of regulatory systems and standards.....	56
5.5 Pathways for regulatory convergence and cooperation.....	58
6. THE ROLE OF REGULATORY CONVERGENCE AND COOPERATION IN THE REGION.....	62
6.1 Platform to collectively address public health concerns.....	63
6.2 Response to emergencies.....	64
6.3 Counterfeit and substandard medicines.....	64
6.4 Antimicrobial resistance.....	65
7. GAPS IN REGULATORY CONVERGENCE AND COOPERATION.....	67
8. WAY FORWARD.....	68
9. RECOMMENDATIONS.....	73
9.1 Recommendations for Member States.....	73
9.2 Recommendations for WHO.....	74
GLOSSARY.....	75

ABBREVIATIONS

AEFI	adverse event following immunization
AHPRA	Australian Health Practitioner Regulation Agency
AMR	antimicrobial resistance
APEC	Asia-Pacific Economic Cooperation
ASEAN	Association of Southeast Asian Nations
CPD	continuing professional development
CPP	certificate of pharmaceutical products
EU	European Union
GMP	good manufacturing practice
GUNTM	Global University Network of Traditional Medicine
HPCA	Health Practitioners Competence Assurance, New Zealand
HPDT	Health Practitioners Disciplinary Tribunal, New Zealand
IAMRA	International Association of Medical Regulatory Authorities
ICDRA	International Conference of Drug Regulatory Authorities
ICH	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
IGBA	International Generic and Biosimilar Medicines Association
IPRF	International Pharmaceutical Regulators Forum
IRCH	International Regulatory Cooperation for Herbal Medicines
IGDRP	WHO-International Generic Drug Regulators' Pilot
MRA	mutual recognition agreement
PIC/S	Pharmaceutical Inspection Co-operation Scheme
PQF	Pacific Qualifications Framework
SSFFC	substandard, spurious, falsely labelled, falsified and counterfeit
TGA	Therapeutic Goods Administration, Australia
UHC	universal health coverage
WHO	World Health Organization

EXECUTIVE SUMMARY

The Western Pacific Regional Action Agenda on Regulatory Strengthening, Convergence and Cooperation for Medicines and the Health Workforce guides Member States on actions to strengthen regulatory systems for medicines and the health workforce. These actions – both at the national level and across national borders – can be implemented most effectively through the cooperative efforts of Member States and by their participation in and the use of global, regional and bilateral convergence and cooperation platforms. Implementation of these actions can help ensure the quality and safety of medicines and the health workforce, which are fundamental to the achievement of universal health coverage.

Situational analysis

Medicines and the health workforce are the most important elements of a well-functioning health system, and they account for the largest share of health system expenditures. The regulatory landscape for medicines and the health workforce is varied across the Western Pacific Region. While some Member States have highly functional regulatory systems, others have relatively weak systems or no formal regulations. In many countries, while legislative frameworks for regulations exist, their implementation and enforcement remain uneven, particularly in relation to traditional medicine.

The introduction of therapeutic products and new technologies and services, as well as the increasing mobility of people and products, increases the need for effective regulatory systems in the Region. While some regulatory systems have evolved to address these changes, others are seriously constrained by resources, leading to an uneven level of regulation and a variability of standards across the Region. This exposes populations in these countries to higher risks of substandard and poor-quality products and unqualified practitioners.

All countries need to strengthen their regulatory systems in order to progress more rapidly towards universal health coverage. However, some countries cannot efficiently and effectively perform all the necessary regulatory functions, particularly in relation to medicines. Alignment with existing international standards and best practices can help strengthen national regulatory systems in those countries that are facing challenges. Further, the convergence of regulatory systems is increasingly important in the context of rapidly changing and globalizing markets for medicines and the health workforce.

Regulatory convergence and cooperation have enabled countries to strengthen their regulatory systems through information sharing; collaboration on setting standards, processes and guidelines; and opportunities for capacity-building and mutual recognition of regulatory functions. Notably, however, there are barriers for participation in existing convergence mechanisms that often leave less-developed countries behind.

Regulation of medicines

Regulatory systems across countries vary widely in terms of the range of regulatory functions performed and the level of capacity. Overall, marketing authorization and inspections of good manufacturing practices are relatively stronger, while pharmacovigilance and market surveillance are relatively weaker. In countries where marketing authorization is weak or non-existent, pharmacovigilance and market surveillance need to be strengthened to protect the population from harmful products.

The number of convergence and cooperation initiatives for the regulation of medicines has been increasing, with potential duplication in some areas. Mostly, only more-developed countries are able to participate in standard-setting initiatives. The Western Pacific Region has among the most advanced national regulatory systems for medicines and medical products in the world, which provides an opportunity for other regions and countries with less-mature regulatory systems to rely on the Western Pacific for training and capacity-building.

Regulation of the health workforce

Regulatory systems across Member States in the Region vary widely in terms of health workforce regulatory arrangements and functions. Patients and communities do not receive the same level of protection nor the same standard of care across all countries. At a time of increased workforce mobility, there is a need for both strong national

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24643

